– SELECT-AXIS 2 highlights the efficacy and safety data of upadacitinib (RINVOQ®) in patients with non-radiographic axial spondyloarthritis, and in patients with radiographic axial spondyloarthritis (ankylosing spondylitis) with an inadequate response to biologic disease-modifying antirheumatic drugs (bDMARDs)- SELECT-PsA 1 & 2 highlight the efficacy and safety data of RINVOQ at two years in psoriatic arthritis (PsA) patients with an inadequate response or intolerance to ≥1 non-biologic DMARD, and in PsA patients with prior inadequate response or intolerance to ≥1 bDMARD, respectively- KEEPsAKE 1 & 2 trials showcase the efficacy and safety data of SKYRIZI ® (risankizumab) in patients with active PsA

Original Source


Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219